Biogen Sinks After Alzheimer's Data Leaves Analysts With Questions

(Bloomberg) -- A presentation on Biogen Inc. Alzheimer’s disease drug sent the shares plunging 10 percent in pre-market trading and reignited a debate on the drug’s effectiveness. It also muddied a...

Bloomberg Quint

Add BloombergQuint App to Home screen.